Theratechnologies (THTX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The market trend for Theratechnologies Inc. (THTX) illustrated on this price chart demonstrates an EV/EBITDA ratio of . Theratechnologies Inc. (THTX) adheres to fundamental environmental standards, focusing on bio-waste disposal during HIV therapy. The business relies on the development of advanced peptide drugs for metabolism correction via protein engineering. Supply stability is ensured by strict adherence to temperature controls during the transportation of immune preparations.
theratech.com - analytical breakdowns and key metrics (THTX)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Theratechnologies Inc.|THTX - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Theratechnologies|THTX - Company Cumulative Debt|Debt to Book Value Theratechnologies, Inc|THTX - Amount of Long-Term Liabilities|Company Short-Term Debts Theratechnologies|Quick Ratio theratech.com
- business earnings and investment ratios data:
THTX - Company Net Income|Expected Profit Theratechnologies Inc.|THTX - Company Value to Net Income|Forward P/E Multiple Theratechnologies Inc.|THTX - PEG Multiple|Enterprise Value to EBITDA Ratio Theratechnologies, Inc|THTX - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Theratechnologies|THTX - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth theratech.com|THTX - Net earnings per share growth this year|Earnings growth forecast for next year Theratechnologies Inc.
Initial company analysis:Theratechnologies Inc (THTX)
For Theratechnologies Inc. (THTX), whose operations focus on the high-cost development of peptide drugs, analyzing business value relative to operating cash flow is critical. The company's EV/EBITDA ratio on this chart correlates the total enterprise value (equity and debt) with earnings before interest, taxes, depreciation, and amortization. An increase in this indicator may signal asset overvaluation amid stagnating real income, while low values confirm the fundamental stability of the issuer's balance sheet.
Competing companies
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|Dianthus Corp - Enterprise Value to Operating Income Before Depreciation Ratio|PHVS: EV/EBITDA Multiple|AbCellera - Business Value to Operating Income Before Depreciation|TRML (Tourmaline Bio) - EV/EBITDA Multiple|Company Value to EBITDA Precigen Inc PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming (PHAR)|NKTR (Nektar Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple UPB (Upstream Bio Inc)|EV/EBITDA Multiple zenasbio.com ZBIO|IMNM: Enterprise Value to EBITDA Ratio|Gossamer Bio Inc - Enterprise Value to Operating Income Before Depreciation Ratio|KALV: EV/EBITDA Multiple|Company Value to EBITDA Septerna Pharma (SEPN)|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio savarapharma.com (SVRA)|EV/EBITDA Multiple RIGL|ANAB (AnaptysBio Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|ENGN: Enterprise Value to Operating Income Before Depreciation|RAPT - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Aerovate Therapeutics Inc|Aclaris Therapeutics, Inc. (ACRS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KYTX (Kyverna Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tiziana Life Sciences PLC|Company Value to EBITDA Cabaletta Bio Inc CABA|EV/EBITDA Multiple VTYX|avalotx.com (AVTX) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple ELDN (Eledon Pharmaceuticals, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Agenus, Inc. (AGEN)|Climb Bio, Inc. - EV/EBITDA Multiple|Company Value to EBITDA zurabio.com|aTyr Pharma, Inc. (ATYR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADAG - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio IMA|STTK: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple EQ|Total Company Value to Operating Income Before Depreciation Ratio connectbiopharm.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic IMUX|ATRA: Enterprise Value to Operating Income Before Depreciation|InflaRx GmbH - EV/EBITDA Multiple|X4 Pharmaceuticals Inc. (XFOR) - Enterprise Value to EBITDA Ratio|ACET (adicetbio.com) - Enterprise Value to EBITDA Ratio|CELU - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio INMB|BRNS (barinthusbio.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KZR|SABS (SAB Biotherapeutics Inc.) - Business Value to Operating Income Before Depreciation|Akari Therapeutics plc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ENLV (Enlivex Therapeutics Ltd)|QTTB: Enterprise Value to EBITDA Ratio|GOVX (geovax.com) - Enterprise Value to Operating Income Before Depreciation|Edesa Biotech (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio IBIO (iBio Inc)|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|XTLB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLT|EV/EBITDA Multiple hcwbiologics.com (HCWB)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|Business Value to Operating Income Before Depreciation AIM|ADTX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GRI Bio Corporation (GRI) - Enterprise Value to EBITDA Ratio|XRTX: EV/EBITDA Multiple|reshapelifesciences.com (HIND) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio REVB|INDP: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SCNI|Total Company Value to Operating Income Before Depreciation Ratio calcimedica.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
